Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
Disclosed herein are hydroxyethylquercetin glycosides, including compounds of Structural Formulas I, II, III and IV. The compounds disclosed are useful for inhibiting norepinephrine metabolism and treating antenatal and postnatal depression in subjects in need thereof.
1. A pharmaceutical composition comprising from about 5% to about 95% weight/weight of a hydroxyethylquercetin-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
2. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral administration.
3. The pharmaceutical composition of claim 1 , further comprising a second acid.
4. The pharmaceutical composition of claim 3 , wherein the second acid is citric acid or hydrochloric acid or a combination thereof.
5. The pharmaceutical composition of claim 1 , wherein the hydroxyethylquercetin-O-glucuronide is a hydroxyethylquercetin-3-O-glucuronide.
6. A pharmaceutical composition comprising from about 5% to about 95% weight/weight of a hydroxyethylquercetin-5-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
7. A pharmaceutical composition comprising from about 5% to about 95% weight/weight of a hydroxyethylquercetin-3′-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
8. A pharmaceutical composition comprising from about 5% to about 95% weight/weight of a hydroxyethylquercetin-4′-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition comprising from about 5% to about 95% weight/weight of a monohydroxyethylquercetin-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
10. The pharmaceutical composition of claim 9 , wherein the monohydroxyethylquercetin-O-glucuronide is a mono-3′-O-hydroxyethyl quercetin-O-glucuronide.
11. A pharmaceutical composition comprising a mono-4′-O-hydroxyethylquercetin-O-glucuronide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
12. A method of inhibiting norepinephrine metabolism in a subject in need thereof, comprising:
administering to the subject an effective amount of the pharmaceutical composition of claim 1 .
13. The method of claim 12 , wherein the administering is orally administering.
14. The method of claim 12 , further comprising administering an acidifier.
15. The method of claim 14 , wherein the acidifier is betaine, or a pharmaceutically acceptable salt thereof.
16. The method of claim 14 , wherein the acidifier is acidic liquid media.
17. The method of claim 16 , wherein the acidic liquid media has a pH of less than about 3.
18. The method of claim 17 , wherein the acidic liquid media comprises citric acid, acetic acid, or hydrochloric acid, or a combination of any of the foregoing.
19. The method of claim 16 , wherein the acidic liquid media comprises vinegar or a citrus juice, or a combination of the foregoing.